OmniAb, Inc. (NASDAQ:OABI) Insider Sells $82,584.36 in Stock

OmniAb, Inc. (NASDAQ:OABI) insider Charles S. Berkman sold 25,489 shares of OmniAb stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $82,584.36. Following the transaction, the insider now owns 343,190 shares in the company, valued at approximately $1,111,935.60. The trade was a 6.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

OmniAb Price Performance

NASDAQ:OABI opened at $3.20 on Friday. OmniAb, Inc. has a 52 week low of $3.11 and a 52 week high of $6.55. The company has a market capitalization of $451.90 million, a P/E ratio of -5.16 and a beta of -0.10. The stock’s fifty day moving average is $3.64 and its two-hundred day moving average is $4.05.

Institutional Investors Weigh In On OmniAb

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Palumbo Wealth Management LLC raised its position in OmniAb by 12.5% in the third quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after purchasing an additional 2,744 shares during the period. Sei Investments Co. grew its stake in shares of OmniAb by 11.0% in the second quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock valued at $109,000 after buying an additional 2,888 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of OmniAb by 16.5% in the fourth quarter. SG Americas Securities LLC now owns 40,609 shares of the company’s stock valued at $144,000 after buying an additional 5,751 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of OmniAb by 64.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after buying an additional 8,909 shares in the last quarter. Finally, Woodstock Corp grew its stake in shares of OmniAb by 1.2% in the fourth quarter. Woodstock Corp now owns 802,578 shares of the company’s stock valued at $2,841,000 after buying an additional 9,725 shares in the last quarter. Hedge funds and other institutional investors own 72.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on OABI shares. Benchmark reiterated a “buy” rating and set a $8.00 price objective on shares of OmniAb in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of OmniAb in a research report on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.